Stock listing
Xetra:BXT BioNxt Solutions Inc Aktie
German listing (Xetra) of BioNxt Solutions Inc · home listing CSE:BNXT
Follow BioNxt Solutions Inc into a list and get an email when it puts out news.
Share price · XETR:BXT
€0.176 EUR +0.012 (+7.3%)
Close on Nov 6, 2026
- Day range
- €0.167 – €0.188 EURNov 6, 2026
- Volume
- 10,505 sharesNov 6, 2026
- Market cap
- €23.88M EURAt the close on Nov 6, 2026 · price × 136.1M shares outstanding
- Traded on an average day
- €5,727 EURMedian day 14,903 shares · last 3 months, Aug 6, 2026 – Nov 6, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| CSE:BNXT · Home | $0.26 CAD | -0.01 (-3.7%) | 11,000 | $0.26 | $0.26 | $0.26 | $0.27 | Close on Nov 6, 2026 |
| Xetra:BXT | €0.176 EUR | +0.012 (+7.3%) | 10,505 | €0.167 | €0.188 | €0.167 | €0.164 | Close on Nov 6, 2026 |
| OTC:BNXTF | $0.205 USD | 0.000 (0.0%) | — | $0.205 | $0.205 | $0.205 | $0.205 | Close on Nov 6, 2026 |
| Frankfurt:BXT | €0.155 EUR | -0.007 (-4.3%) | 1,500 | €0.158 | €0.158 | €0.147 | €0.162 | Close on Nov 6, 2026 |
Daily closes
Last 3 months, Aug 6, 2026 – Nov 6, 2026 · XETR:BXT · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.176 | +0.012 | +7.3% | €0.167 | €0.188 | €0.167 | 10,505 | |
| €0.164 | -0.014 | -7.9% | €0.182 | €0.188 | €0.164 | 12,388 | |
| €0.178 | -0.014 | -7.1% | €0.189 | €0.189 | €0.178 | 17,214 | |
| €0.191 | -0.008 | -4.0% | €0.190 | €0.200 | €0.182 | 5,590 | |
| €0.199 | +0.010 | +5.0% | €0.180 | €0.199 | €0.180 | 3,218 | |
| €0.190 | +0.008 | +4.1% | €0.180 | €0.190 | €0.180 | 10,700 | |
| €0.182 | -0.005 | -2.7% | €0.181 | €0.190 | €0.181 | 20 | |
| €0.187 | +0.006 | +3.3% | €0.188 | €0.188 | €0.187 | 2,500 | |
| €0.181 | +0.008 | +4.3% | €0.187 | €0.195 | €0.181 | 7,122 | |
| €0.174 | -0.021 | -10.8% | €0.185 | €0.196 | €0.174 | 686 | |
| €0.195 | +0.003 | +1.3% | €0.196 | €0.196 | €0.195 | 850 | |
| €0.192 | -0.018 | -8.6% | €0.193 | €0.193 | €0.192 | 24,972 | |
| €0.210 | 0.000 | 0.0% | €0.197 | €0.210 | €0.182 | 24,972 | |
| €0.210 | -0.002 | -0.9% | €0.197 | €0.210 | €0.195 | 32 | |
| €0.212 | 0.000 | 0.0% | €0.213 | €0.213 | €0.195 | 14,903 | |
| €0.212 | +0.014 | +7.3% | €0.198 | €0.212 | €0.183 | 36,885 | |
| €0.198 | 0.000 | 0.0% | €0.182 | €0.198 | €0.182 | 137 | |
| €0.198 | +0.002 | +1.0% | €0.198 | €0.200 | €0.198 | 9,725 | |
| €0.196 | -0.011 | -5.6% | €0.197 | €0.211 | €0.189 | 750 | |
| €0.207 | -0.001 | -0.5% | €0.197 | €0.212 | €0.183 | 8,698 | |
| €0.208 | -0.008 | -3.7% | €0.181 | €0.223 | €0.180 | 63,505 | |
| €0.216 | -0.005 | -2.3% | €0.221 | €0.221 | €0.200 | 36,739 | |
| €0.221 | +0.010 | +4.7% | €0.223 | €0.223 | €0.211 | 5,842 | |
| €0.211 | -0.011 | -5.0% | €0.223 | €0.223 | €0.211 | 10,136 | |
| €0.222 | -0.011 | -4.7% | €0.227 | €0.233 | €0.210 | 97,811 | |
| €0.233 | +0.006 | +2.6% | €0.220 | €0.233 | €0.220 | 27,559 | |
| €0.227 | +0.002 | +0.9% | €0.226 | €0.234 | €0.216 | 15,488 | |
| €0.225 | -0.003 | -1.3% | €0.225 | €0.233 | €0.217 | 4,749 | |
| €0.228 | +0.003 | +1.3% | €0.225 | €0.234 | €0.225 | 12,122 | |
| €0.225 | -0.010 | -4.3% | €0.216 | €0.234 | €0.216 | 25,717 | |
| €0.235 | 0.000 | 0.0% | €0.225 | €0.235 | €0.214 | 42,086 | |
| €0.235 | +0.001 | +0.4% | €0.224 | €0.235 | €0.213 | 44,994 | |
| €0.234 | +0.008 | +3.5% | €0.225 | €0.235 | €0.213 | 17,408 | |
| €0.226 | +0.013 | +6.1% | €0.224 | €0.248 | €0.213 | 116,571 | |
| €0.213 | +0.004 | +1.9% | €0.213 | €0.237 | €0.213 | 76,279 | |
| €0.209 | +0.001 | +0.5% | €0.222 | €0.235 | €0.209 | 9,710 | |
| €0.208 | -0.004 | -1.9% | €0.224 | €0.235 | €0.208 | 19,703 | |
| €0.212 | 0.000 | 0.0% | €0.224 | €0.230 | €0.212 | 49,158 | |
| €0.212 | -0.022 | -9.4% | €0.235 | €0.235 | €0.209 | 10,431 | |
| €0.234 | +0.004 | +1.7% | €0.222 | €0.235 | €0.221 | 17,918 | |
| €0.230 | -0.003 | -1.3% | €0.222 | €0.230 | €0.218 | 24,247 | |
| €0.233 | -0.001 | -0.4% | €0.223 | €0.233 | €0.201 | 20,312 | |
| €0.234 | +0.018 | +8.3% | €0.228 | €0.234 | €0.202 | 86,139 | |
| €0.216 | -0.007 | -3.1% | €0.230 | €0.232 | €0.204 | 66,363 | |
| €0.223 | +0.013 | +6.2% | €0.210 | €0.231 | €0.200 | 118,358 | |
| €0.210 | +0.005 | +2.4% | €0.235 | €0.235 | €0.203 | 108,404 | |
| €0.205 | -0.022 | -9.7% | €0.234 | €0.235 | €0.205 | 7,699 | |
| €0.227 | +0.007 | +3.2% | €0.225 | €0.233 | €0.225 | 21,342 | |
| €0.220 | -0.008 | -3.5% | €0.220 | €0.220 | €0.220 | 1,600 | |
| €0.228 | -0.007 | -3.0% | €0.220 | €0.236 | €0.220 | 75,450 | |
| €0.235 | +0.015 | +6.8% | €0.235 | €0.235 | €0.216 | 4,470 | |
| €0.220 | +0.004 | +1.9% | €0.230 | €0.235 | €0.220 | 37,282 | |
| €0.216 | -0.004 | -1.8% | €0.200 | €0.227 | €0.200 | 31,838 | |
| €0.220 | +0.005 | +2.3% | €0.220 | €0.220 | €0.220 | 5,622 | |
| €0.215 | -0.005 | -2.3% | €0.215 | €0.215 | €0.210 | 48,856 | |
| €0.220 | +0.005 | +2.3% | €0.218 | €0.230 | €0.210 | 70,849 | |
| €0.215 | +0.015 | +7.5% | €0.200 | €0.215 | €0.200 | 19,469 | |
| €0.200 | +0.009 | +4.7% | €0.208 | €0.208 | €0.200 | 63,214 | |
| €0.191 | -0.014 | -6.8% | €0.200 | €0.209 | €0.191 | 3,901 | |
| €0.205 | +0.025 | +13.9% | €0.204 | €0.208 | €0.204 | 4,452 | |
| €0.180 | 0.000 | 0.0% | €0.207 | €0.209 | €0.180 | 25,147 | |
| €0.180 | -0.001 | -0.6% | €0.187 | €0.209 | €0.180 | 1,517 | |
| €0.181 | -0.019 | -9.3% | €0.210 | €0.210 | €0.181 | 4,156 | |
| €0.200 | +0.001 | +0.3% | €0.211 | €0.211 | €0.192 | 11,181 | |
| €0.199 | -0.001 | -0.3% | €0.204 | €0.206 | €0.199 | 10,205 | |
| €0.200 | +0.013 | +6.7% | €0.214 | €0.214 | €0.191 | 1,521 | |
| €0.187 | -0.025 | -11.8% | €0.179 | €0.214 | €0.179 | 754 |
- Ticker
- Xetra:BXT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Xetra
- Currency
- EUR
What changed lately
Latest news release · Oct 19, 2026
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 27 slides
Latest news
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
Oct 19, 2026
Closed €0.212 (0.0%) on Oct 19, 2026
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
Sep 8, 2026
Closed €0.216 (-3.1%) on Sep 8, 2026
BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants
Aug 21, 2026
Closed €0.215 (-2.3%) on Aug 24, 2026
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
Aug 4, 2026
Closed €0.216 (-1.4%) on Aug 4, 2026
BioNxt Solutions Announces Option Grants
Jul 31, 2026
Closed €0.219 (+18.4%) on Aug 3, 2026
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
Jul 6, 2026
Closed €0.205 (-12.8%) on Jul 6, 2026
BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Jun 23, 2026
Closed €0.237 (-11.9%) on Jun 24, 2026
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
Jun 15, 2026
Closed €0.225 (-1.7%) on Jun 15, 2026
BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Jun 12, 2026
Closed €0.225 (-1.7%) on Jun 15, 2026
BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants
Jun 10, 2026
Closed €0.23 (-4.2%) on Jun 11, 2026
Financings
Private placement of units
Jun 23, 2026 · US$1.41M
Closed: C$2M raised · C$0.33 a unit · 1 warrant at C$0.5 for 24 months
Use of proceeds: European research and development and operations, working capital and general corporate purposes
Private placement of units
Jun 12, 2026 · US$1.43M
Announced: up to C$2M · C$0.33 a unit · 1 warrant at C$0.5 for 24 months
Use of proceeds: European research and development and operations, working capital and general corporate purposes
Private placement of convertible debenture units
Aug 8, 2025
Closed: C$1.25M raised · C$0.6 a unit · 1 warrant at C$0.75 for 24 months · Canaccord Genuity Corp. · free to trade Dec 9, 2025
Dealers: Canaccord Genuity Corp. (finder)
Use of proceeds: Product development and commercialization, intellectual property filings, and general working capital
Announced Jul 11, 2025 · Tranche closed Jul 25, 2025 · Closed Aug 8, 2025
Convertible debenture units
Mar 14, 2025
Closed: C$2.5M raised · C$0.5 a unit · 1 warrant at C$0.6 for 24 months · Canaccord Genuity Corp. · free to trade Jul 15, 2025
Dealers: Canaccord Genuity Corp. (finder)
Use of proceeds: Product development and commercialization, intellectual property filings, debt repayment, and general working capital
Decks
Investor Presentation (September 2026)
Investor deck · 27 slides · September 2026
Investor Presentation (November 2024)
Investor deck · 23 slides · November 2024
XPhyto Therapeutics — Investor Presentation (June 2021)
Investor deck · 16 slides · June 2021
BioNxt Solutions Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 26 in the last 12 months · 66 in all · newest Oct 19, 2026 · oldest 2024
- Decks
- 3 decks · latest September 2026
Where BioNxt Solutions Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| CSE:BNXT · Home listing | CSE | Canada | CAD |
| Xetra:BXT · This page | Xetra | Germany | EUR |
| gettex:BXT | gettex | Germany | EUR |
| LS Exchange:A3D1K3 | LS Exchange | Germany | EUR |
| Tradegate:BXT | Tradegate | Germany | EUR |
| Lang & Schwarz:A3D1K3 | Lang & Schwarz | Germany | EUR |
| Cboe Canada:BNXT | Cboe Canada | Canada | CAD |
| OTC:BNXTF | OTC | United States | USD |
| Frankfurt:BXT | Frankfurt | Germany | EUR |
| Dusseldorf:BXT | Dusseldorf | Germany | EUR |
| Hamburg:BXT | Hamburg | Germany | EUR |
| Munich:BXT | Munich | Germany | EUR |
| Stuttgart:BXT | Stuttgart | Germany | EUR |
| Hanover:BXT | Hanover | Germany | EUR |
Log in to ask 6ix AI your own questions about BioNxt Solutions Inc.